BNGO vs. PRPO, STAI, DAIO, MSAI, ASTC, TLIS, SMIT, TBIO, SPEC, and THMO
Should you be buying Bionano Genomics stock or one of its competitors? The main competitors of Bionano Genomics include Precipio (PRPO), ScanTech AI Systems (STAI), Data I/O (DAIO), MultiSensor AI (MSAI), Astrotech (ASTC), Talis Biomedical (TLIS), Schmitt Industries (SMIT), Telesis Bio (TBIO), Spectaire (SPEC), and ThermoGenesis (THMO). These companies are all part of the "measuring and control equipment" industry.
Bionano Genomics vs. Its Competitors
Bionano Genomics (NASDAQ:BNGO) and Precipio (NASDAQ:PRPO) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their valuation, media sentiment, risk, analyst recommendations, profitability, institutional ownership, dividends and earnings.
In the previous week, Bionano Genomics had 1 more articles in the media than Precipio. MarketBeat recorded 1 mentions for Bionano Genomics and 0 mentions for Precipio. Precipio's average media sentiment score of 0.00 beat Bionano Genomics' score of -1.00 indicating that Precipio is being referred to more favorably in the news media.
11.4% of Bionano Genomics shares are owned by institutional investors. Comparatively, 10.4% of Precipio shares are owned by institutional investors. 0.9% of Bionano Genomics shares are owned by insiders. Comparatively, 16.9% of Precipio shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.
Precipio has lower revenue, but higher earnings than Bionano Genomics. Precipio is trading at a lower price-to-earnings ratio than Bionano Genomics, indicating that it is currently the more affordable of the two stocks.
Bionano Genomics has a beta of 2.19, suggesting that its share price is 119% more volatile than the S&P 500. Comparatively, Precipio has a beta of 1.18, suggesting that its share price is 18% more volatile than the S&P 500.
Bionano Genomics currently has a consensus target price of $7.50, suggesting a potential upside of 294.74%. Given Bionano Genomics' stronger consensus rating and higher possible upside, analysts plainly believe Bionano Genomics is more favorable than Precipio.
Precipio has a net margin of -8.48% compared to Bionano Genomics' net margin of -271.02%. Precipio's return on equity of -15.00% beat Bionano Genomics' return on equity.
Summary
Bionano Genomics and Precipio tied by winning 8 of the 16 factors compared between the two stocks.
Get Bionano Genomics News Delivered to You Automatically
Sign up to receive the latest news and ratings for BNGO and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding BNGO and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Bionano Genomics Competitors List
Related Companies and Tools
This page (NASDAQ:BNGO) was last updated on 10/18/2025 by MarketBeat.com Staff
